Seattle, WA, April 07, 2018 --(PR.com
)-- AirDoc, the leader in artificial intelligence for healthcare, announced that it has completed a Series B financing led by Fosun Investments and Sogou Investments, and the three parties will jointly explore a better integration of their product lines for medical artificial intelligence. In addition, AirDoc announced the launch of an online and offline integration of Fosun and Sogou's intelligent prevention and control system for chronic diseases.
After more than 3 years of development, the AirDoc team has built an artificial intelligence chronic disease recognition system, including a retina/fundus-based algorithm that can identify more than 30 chronic diseases, including systemic chronic disease complications such as diabetes, hypertension, arteriosclerosis, and optic nerve diseases, as well as glaucoma, age-related macular degeneration and other common eye diseases.
To ensure high quality, AirDoc has collected millions of medical images from the world's top medical institutions, including the top-ranking eye hospitals in China, to build multi-layer convolutional neural networks. The data labels of each sample were independently marked and cross-controlled by multiple skilled industry experts, thus ensuring the rigor of the data materials.
AirDoc founder and CEO Zhang Dalei said, "AirDoc's AI medical image recognition technology has become an indispensable tool at hundreds of medical institutions in the United States and China. Every day, more than 100,000 doctors use AirDoc Ask to assist in their decision-making. Our new close relationship with Fosun and Sogou will help jointly build a new era of comprehensive health with doctors and patients as the center."
In the past three years, AirDoc has conducted screening for chronic diseases in many provinces and cities throughout China including Beijing, Shanghai, Hainan, Jiangsu, Hebei, and Anhui, providing tens of thousands of people with rapid diagnosis suggestions every day. After this round of financing is completed, AirDoc will bring to market a wide range of application scenarios and business models based on its current successful pilots. The additional investment will also enable AirDoc to conduct comprehensive collaboration with hospitals, insurance companies, pharmaceutical companies, and health management companies to accelerate medical AI technology.
According to Chen Qiyu, executive director and co-president of Fosun International, "Fosun attaches great importance to the organic integration of new technologies and business, and also actively invests in new technologies with potential in independent research and development. AirDoc’s highly accurate chronic disease screening technology combined with Fosun's products, services and healthcare systems will be an efficient enabler of artificial intelligence and effectively contribute to the healthy China strategy."
Sogou CEO Wang Xiaochuan stated, "We are very happy to be two round investors of AirDoc. We hope to promote the practical application of medical AI. Following last year’s launch of our medical product 'Sougou Mingmei,' we now provide users with authoritative and real medical information services plus state-of-the-art AI technology to conduct preliminary triages based on users' symptoms. We are very optimistic about the auxiliary diagnostic system developed by AirDoc and its wide range of application scenarios. We believe that deep cooperation between the two parties can create medical AI products that benefit everyone more quickly."
Founded in 2015, AirDoc is an artificial intelligence leader in the medical field with branches in multiple cities throughout China and the United States. Based on its pioneering work on medical artificial intelligence, AirDoc has been selected as the Secretary General of the China Association of Artificial Intelligence Smart Healthcare Committee and the China Association for Health Promotion and Education. Health Branch Standing Committee. As one of the earliest companies in the world to begin clinical application of an auxiliary diagnosis system based on deep learning, AirDoc has participated in the drafting of relevant standards and specifications for medical artificial intelligence at home and abroad. It is also the operating unit of the STI Intelligent Medical Imaging Center of the Ministry of Science and Technology.
Fosun and its subsidiaries manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services to promote health, happiness and prosperity. Fosun was founded in 1992. In 2007, Fosun International was listed on the Main Board of the Hong Kong Stock Exchange (00656.HK). As of December 31, 2017, Fosun's total assets exceeded RMB530 billion.